Market Data 
Markets
Replies to post #21338 on Rich Pharmaceuticals Inc. (fka RCHA)
So where might the news be coming from?
As of a couple months ago, we learned that Rich had picked up approval for an investigational new drug (IND) application from the FDA related to its lead oncology asset. The drug in question is called RP-323 and, if it’s mechanism of action proves effective, it could be a real winner for both its target patient population and Rich and its shareholders going forward.
Its mechanism of action (MOA) is pretty complicated but it can be simplified as follows: the drug activates what’s called protein kinase C (PKC), which then produces something called NF kappa. NF kappa then produces NF kappa B, which is a protein complex that is able to enter the nucleus of cells. When something enters a cell’s nucleus it has the ability to change the activity of the cell in question and, in this instance, the NF kappa B enters the nuclei of cancer cells and induces apoptosis, which is a sort of mechanical cell death that doesn’t work as it should in cancer cells and, in turn, leads to the excessive proliferation associated with the disease.
Anyway, in this instance, the company is trying to put this MOA to work in a target indication of acute myeloid leukemia (AML) and Hodgkin’s lymphoma (HL), both of which are blood cancers and both of which, theoretically, RP-323 should be able to combat.
Bottom line here is that volume is picking up and share price remains subdued, but any news should get things moving far and fast and there is plenty of scope for near-term operational updates. There is a dilution risk rooted in the necessity to fund the ongoing clinical trial, but any raise should be outweighed by the upside revaluation once some fresh information hits the tape.
10/09/17 1:04 PM
10/10/17 2:04 PM
10/10/17 8:24 PM
10/11/17 5:47 AM
AI
